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Abstract
Background: To explore ways to reduce the overuse of antibiotics for acute respiratory infections (ARIs), we
conducted a pilot clustered randomized controlled trial (RCT) to evaluate DECISION+, a training program in shared
decision making (SDM) for family physicians (FPs). This pilot project demonstrated the feasibility of conducting a
large clustered RCT and showed that DECISION+ reduced the proportion of patients who decided to use
antibiotics immediately after consulting their physician. Consequently, the objective of this study is to evaluate, in
patients consulting for ARIs, if exposure of physicians to a modified version of DECISION+, DECISION+2, would
reduce the proportion of patients who decide to use antibiotics immediately after consulting their physician.
Methods/design: The study is a multi-center, two-arm, parallel clustered RCT. The 12 family practice teaching units
(FPTUs) in the network of the Department of Family Medicine and Emergency Medicine of Université Laval will be
randomized to a DECISION+2 intervention group (experimental group) or to a no-intervention control group. These
FPTUs will recruit patients consulting family physicians and residents in family medicine enrolled in the study.
There will be two data collection periods: pre-intervention (baseline) including 175 patients with ARIs in each study
arm, and post-intervention including 175 patients with ARIs in each study arm (total n = 700). The primary
outcome will be the proportion of patients reporting a decision to use antibiotics immediately after consulting
their physician. Secondary outcome measures include: 1) physicians and patients’ decisional conflict; 2) the
agreement between the parties’ decisional conflict scores; and 3) perception of patients and physicians that SDM
occurred. Also in patients, at 2 weeks follow-up, adherence to the decision, consultation for the same reason,
decisional regret, and quality of life will be assessed. Finally, in both patients and physicians, intention to engage in
SDM in future clinical encounters will be assessed. Intention-to-treat analyses will be applied and account for the
nested design of the trial will be taken into consideration.
Discussion: DECISION+2 has the potential to reduce antibiotics use for ARIs by priming physicians and patients to
share decisional process and empowering patients to make informed, value-based decisions.
Trial Registration: ClinicalTrials.gov: NCT01116076
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The use of antibiotics for acute respiratory infections
(ARIs) has been likened to the tragedy of the com-
mons–an event where individuals who acted locally for
their own benefit inadvertently contributed to cata-
strophe at the ecological level [1]. ARIs are the main
reported reason why patients consult primary care phy-
sicians in North America [2]. In a study that assessed
the accuracy of primary care physicians’ billing claims in
the province of Quebec, Canada, 1,173 of 3,526 visits
(33.3%) produced a diagnosis of ARI later confirmed by
chart audit [3]. Yet the rate of use of antibiotics for
ARIs is well above the expected prevalence of bacterial
infection. For example, in a study based on` the
National Research System of the College of Family Phy-
sicians of Canada, of 408 clinical encounters for respira-
tory tract infections (52.6% for acute bronchitis, 23.3%
for an undiagnosed condition and 15.5% for viral ill-
ness), in 56.9% of visits, the patient received antibiotics
immediately [4]. This figure contrasts with the study’s
observation that in 70% of the encounters, family physi-
cians (FPs) expressed uncertainty about the need for
antibiotics [4]. A second study, this one of Ontario chil-
dren under 16, recorded that of 4344 observed visits,
1706 resulted in a prescription for antibiotics [5]. Of
these prescriptions, 1577 (92%) were for ARIs, of which
920 (53%) were for acute otitis media; a full course of
antibiotics was given to 321 (76%) of 425 children with
pharyngitis immediately [5]. Given that only 38% of
adults with acute rhinosinusitis, 6 to 18% of children
with an ARI, and 5 to 15% of adults with pharyngitis
have a bacterial infection [6,7], this suggests that anti-
biotics are overused, a phenomenon that in the words of
Patrick and Hutchison (2009) may build a population’s
resistance to antibiotics and reduce the success of future
therapy [1].
To date, attempts to improve the clinical decision-
making process regarding the use of antibiotics for ARIs
have been moderately effective at best [8]. The clinical
decision-making process is not always simple, as it
requires the parties to reconcile different expertise: that
of the health provider, considered a medical expert, and
that of the patient, considered an expert in his/her per-
sonal values [9]. It is that context of dual knowledge
that is of interest to research in shared decision making
(SDM). Said to be the crux of patient-centred care [10],
SDM is a process in which a healthcare choice is made
by the clinician and the patient, working together [11].
In the context of deciding whether to use antibiotics for
ARIs, the patient would participate in the decision by
clarifying what s/he values most: maximizing the prob-
ability of recovery or minimizing the probability of side
effects. SDM promotes decision making in the context
of scientific uncertainty because it exposes the uncer-
tainty inherent to the clinical decision-making process
by requiring the parties to discuss benefits and risks
[12]. In others words, SDM is about improving the
patient-clinician decision-making process so that deci-
sions lead to a choice that is not only informed by the
best evidence but is also in line with what patients most
value. We argue that SDM has the potential to improve
the clinical decision-making process regarding antibiotic
use for ARIs by empowering patients (again through
enhanced communication skills and prognostic under-
standing) to make informed decisions about when to
take further action [13,14].
In 2008, we completed a pilot clustered randomized
controlled trial (RCT) studying antibiotics prescriptions
for ARIs in primary care [15]. We randomized four
family medicine groups (FMGs) to an intervention
group (two FMGs, 18 FPs, and 173 patients) or to a
control group (two FMGs, 15 FPs, and 147 patients).
We found that FPs’ exposure to DECISION+, a multifa-
ceted intervention for implementing SDM in medical
practices that included training, reminders and feedback,
was associated with a decrease in decisions for “immedi-
ate antibiotics” compared to decisions for “delayed/no
antibiotics” (49% vs. 33% absolute difference = 16%; p =
0.08 and relative risk = 0.69; 95% CI: 0.47-1.03). By
“immediate antibiotics,” we refer to the patient’s deci-
sion, made during the consultation, to use antibiotics
immediately to treat the ARI. Associated with the main
outcomes of this pilot trial that demonstrated the feasi-
bility and acceptability [16], we are now conducting a
large clustered RCT of a modified version of DECISION
+, DECISION+2. The proposed trial will be the first
RCT with sufficient statistical power to assess the
impact of DECISION+2 on ARI patients reporting a
decision to use antibiotics immediately. This informa-
tion will inform strategies that cause the parties to work
together to improve the clinical decision-making process
f o rt h et r e a t m e n to fA R I s .I ns od o i n g ,t h eR C Tw i l l
address the problem of antibiotic overuse for ARIs in
primary care and eventually improve population health.
The proposed RCT is based on our conceptual frame-
work [17] and the results of the pilot RCT [15,16]. Its
first objective is to evaluateh o wD E C I S I O N + 2i m p a c t s
the proportion of ARI patients reporting a decision to
use antibiotics immediately. The other objectives are to
estimate the impact of DECISION+2 on 1) the decisio-
nal conflict scores of physicians and their patients and
the level of agreement between their scores, 2) percep-
tion of patients and physicians that SDM occurred,
3) patients’ adherence to the decision made, 4) consulta-
tion for the same reason, 5) patients’ decisional regret,
6) patients’ quality of life, and 7) physicians and patients’
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dealing with antibiotics for ARIs.
Methods/Design
Study design
The study is a multi-center, two-arm, parallel clustered
RCT conducted in the network of the 12 family practice
teaching units (FPTUs) from the Department of Family
and Emergency Medicine at Université Laval. All FPTUs
that will accept to participate will be randomly allocated
to either 1) an experimental group that is exposed to
the DECISION+2 intervention or 2) a control group
with no intervention. Two data collection periods are
planned for each study group: the first before the DECI-
SION+2 intervention is offered and the second after the
post-DECISION+2 intervention.
Study population
Family Practice Teaching Units and their Family Physicians
Following the approval by Family Medicine residency
program committee at Université Laval, the 12 FPTU
directors will be contacted by means of a letter sent by
the research team briefly explaining that a new SDM
training course addressing the use of antibiotics in the
context of ARIs will be formally evaluated by means of
a RCT, and that the participation of their FPTU to the
trial would be appreciated. Meetings with all health pro-
fessionals in interested FPTU will be organized to
further explain implications of participating to the trial.
All FPs, both teachers and residents, who provide care
in the FPTU’s walk-in clinics, will be eligible to partici-
pate in the trial. FPs will be excluded from the study if
they were involved or had participated in the DECI-
SION+ pilot RCT, or if they do not expect to practice at
the FPTU for the study duration (e.g., residents ending
their residency program, physicians doing rotations out-
side of the FPTU, physicians who expect to be pregnant,
physicians planning to retire).
Should the FPTU agree to participate, the FPTU
director will sign a letter to this effect. The letter will be
returned to the research institution’s ethics committee.
All participants will sign an informed consent form
approved by the research institution’s ethics committee.
Patients
Patients will be included if 1) they are ≥ 18 years old; if
they are ≤17 years old but are accompanied by a parent
or legal guardian; 2) they are consulting a participating
physician for an ARI (e.g., acute otitis media, acute rhi-
nosinusitis, acute pharyngitis, or acute bronchitis) for
which an antibiotic treatment may be considered;
3) either the patient or the accompanying parent or
guardian is able to read, understand and write French
(expected level: Grade 8); and 4) they sign the informed
consent form approved by the ethics committee of the
Centre de Santé et des Services Sociaux de la Vieille-
Capitale. This ethics committee approved this project
on June 14
th 2010. Patients with a condition requiring
emergency care will not be eligible to participate.
Interventions
Experimental group
In line with the Family Medicine residency program
courses and following an in-depth evaluation with parti-
cipants to the pilot trial [18], the original DECISION+
training program (i.e., 3 three-hour on-site interactive
workshops, reminders and feedback) was modified to
include a 2-hour web-based tutorial followed by a
2-hour on-site interactive workshop followed by remin-
ders. The web-based tutorial addresses key components
of the clinical decision-making process regarding anti-
biotic treatments for ARIs in primary care: 1) the prob-
abilistic nature of a diagnosis of a bacterial versus a viral
infection; 2) scientific evidence regarding the risk/benefit
ratios of the options; 3) communication techniques; and
4) strategies to foster patients’ participation in the deci-
sion-making process [17]. The interactive workshop
aims to help physicians to review and integrate the con-
cepts they acquired during the web-based training in
such a way as to promote their patients’ participation in
SDM. Both the tutorial and the workshop include
videos, exercises and decisional support tools to help
FPs communicate to patients the probability of a bacter-
ial ARI and the benefit/risk ratio associated with the use
of antibiotics. Reminders will consist in the following
strategy: during the second data collection period,
research assistants will give participating physicians in
the intervention group the decision support tools before
recruiting ARI patients. In this large clustered RCT, the
feedback component of the original DECISION+ train-
ing program will not be used.
Participants will have one month to complete the
web-based self-tutorial, which lasts approximately
120 minutes. Collaborators have tested and appraised
the web-based platform associated with the tutorial.
After the tutorial completion period, the on-site interac-
tive workshop will be offered to the experimental group.
The on-site interactive workshop will be led by
team members and facilitators trained during the DECI-
SION+ pilot RCT. The facilitators of the workshop will
be further trained during a standardization session prior
to conducting the workshop in their FPTU. During the
workshop participating FPs and residents will be
instructed to use the material and decision support tools
with their patients.
Control group
The FPs and the patients in the control group will not
receive any particular intervention during the trial per-
iod. No specific course or training activity on SDM or
Légaré et al. BMC Family Practice 2011, 12:3
http://www.biomedcentral.com/1471-2296/12/3
Page 3 of 6on treatment of ARIs will be planned in the control
FPTU over this period. In addition to avoid contamina-
tion bias, access to the web-based platform will be
denied to the control group participants during the trial.
The control group will be offered the experimental
training after the completion of the proposed trial.
Allocation of participants to trial groups
In this study, our unit of randomization is the FPTU.
Randomization of all FTPU accepting to participate to
the trial will be performed simultaneously by an experi-
enced biostatistician who will use Internet-based soft-
ware. Simultaneous randomization of all participating
unit assures allocation concealment.
Outcome measures
Primary outcome
The primary outcome will be the proportion of patients
reporting a decision to use antibiotics immediately.
The decision to use antibiotics
After each clinical encounter for ARIs (e.g., acute otitis
media, acute bronchitis, acute pharyngitis, or acute rhi-
nosinusitis), patients and their FPs will indicate whether
they discussed the use of antibiotic to treat the ARI and
whether they decided to use antibiotics immediately,
delay using antibiotics, or not use antibiotics. In the
context of antibiotic overuse for ARI, limiting the deci-
sion for “immediate antibiotics” is the important target
to achieve. Therefore, we will combine “delayed” and
“no antibiotics” i n t oas i n g l ec a t e g o r ya n dc o n t r a s ti t
with “immediate antibiotics.”
We will validate patients’ answers 1) by asking them
to show their prescription to the research assistant, if
applicable, who will note the medication prescribed and
the date for filling the prescription, if given; and 2) by
asking the same question to the FP after the index con-
sultation. In our pilot RCT, agreement between FPs and
patients was very high (Kappa = 0.90; p < 0.001) [15,16].
Secondary outcomes
Secondary outcome measures assess the impact of
DECISION+2 by evaluating: 1) physicians and patients’
decisional conflict; 2) the agreement between the parties’
decisional conflict scores; and 3) perception of patients
and physicians that SDM occurred. In patients, we will
also assess at 2 weeks: 1) adherence to the decision;
2) consultation for the same reason; 3) decisional regret;
and 4) quality of life. Also, in both patients and FPs, we
will assess their intention to engage in SDM in clinical
encounters dealing with the use of antibiotics for ARIs
in the future.
Decisional conflict
Decisional conflict will be assessed by administering the
Decisional Conflict Scale after the clinical encounter.
This questionnaire is similar for physicians and patients.
It includes 19 items, each of which is scored on a
5-point Likert scale (1 = strongly agree to 5 = strongly
disagree) where higher scores are associated with greater
decisional conflict. Both the physician and the patient
versions of the scale have adequate psychometric
properties [15,19].
Perception of patients and physicians that SDM occurred
The perception of patients and FPs that SDM occurred
will be assessed using a self-administered questionnaire,
D-OPTION, derived from the original third observer
instrument, OPTION [20,21].
Adherence to the decision
Two weeks after the clinical encounter, in a telephone
interview, a research assistant will ask the patient two
questions regarding their adherence to the decision:
“Two weeks ago, what decision did you make with your
FP about using antibiotics for your ARI?” (to use anti-
biotics immediately, delay using antibiotics, or not use
antibiotics). and “Can you say that you maintained this
decision?” (yes or no). If patient answers no, the
research assistant will use an open-ended question to
inquire about his/her reasons and determine what the
patient did instead.
Consultation for the same reason
In line with the index consultation for which they were
included in this trial, we will ask patients a simple ques-
tion: “In the past two weeks, have you consulted a pri-
mary care provider for the same reason or for the same
clinical problem?” (yes or no).
Decisional regret
During the same telephone call, the research assistant
will assess the patient’s decisional regret using the Deci-
sional Regret Scale. The Decisional Regret Scale is a
5-item scale with efficient psychometric properties that
correlates strongly with decision satisfaction and overall
quality of life [22].
Quality of life
Patients’ quality of life will be assessed, immediately
before and two weeks after the clinical encounter. In
both cases, the research assistant will use the Short
Form-12 questionnaire (SF-12V2 Health survey) [23] to
measure the patient’s general health status from his/her
point of view. This questionnaire evaluates eight ele-
ments commonly held to represent health status: physi-
cal fitness, role functioning, pain, general health, vitality,
social abilities, and emotional and mental health.
Intention to engage in SDM in future consultations dealing
with antibiotics for ARIs
This intention on the part of FPs and their patients will
be assessed by questionnaire in reference to the Theory
of Planned Behaviour [24]. Composed of 15 items
scored with a 7-point Likert scale, the questionnaire
covers the theory’s constructs, namely, attitudes,
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intention. Patients will complete this questionnaire
before and 2 weeks after the clinical encounter; physi-
cians will complete it once during the baseline data col-
lection period and once again after the post-intervention
data collection period. From a theoretical perspective,
the questionnaire will ensure that we understand what
underlying mechanisms should be considered when
developing interventions to apply SDM in primary care.
Other variables (potential effect modifiers)
Sociodemographic characteristics
Before the clinical encounter, patients will be assessed in
terms of the following sociodemographic characteristics:
age, gender, highest educational degree, employment,
annual household income, size of household, marital
status and health. FPs’ characteristics will also be deter-
mined before the clinical encounter, during the first
data collection period. We will assess FPs’ age, number
of years in practice, gender, number of formal years of
education, other degrees, participation in committees,
continuing professional development activities, and anxi-
ety about uncertainty and disclosing uncertainty to
patients [25,26].
Data collection procedures
There will be two data collection periods: pre-interven-
tion (baseline) and post-intervention. We will record
data for FPs once during the baseline phase. Patients’
characteristics will be recorded before their clinical
encounter with the physician. After the clinical encoun-
ter, the patient and the physician will independently
complete self-administered questionnaires that will
assess both the decision that had been made (the pri-
mary outcome) and decisional conflict. Both the patient
and the physician will also assess independently if SDM
occurred. Patients will be contacted by phone two weeks
after the clinical encounter to complete a short inter-
view (adherence to the decision, consultation for the
same reason, decisional regret, quality of life, and inten-
tion to engage in SDM). FPs’ intention to engage in
SDM regarding the use of antibiotics for ARIs will be
recorded at baseline and again at the end of the study.
Sample size and analysis
The primary outcome is whether or not patients report
a decision for immediate use of antibiotics for ARI after
an index consultation. In the pilot RCT, immediate use
of antibiotics was 56% in the experimental group and
54% in the control group at baseline. We assume that
the minimum clinical significance for an absolute reduc-
tion of immediate use of antibiotics is 20%. In order to
detect a reduction from 60% to 40% with 80% power, at
a 5% significance level, one would require a total of 194
patients in an individually randomized two-group trial.
To take account of the clustering of participants within
FPTU (unit of randomisation), we used an intracluster
correlation coefficient (ICC) of 0.02 estimated from our
pilot cluster RCT [15,16]. Therefore, we will need 288
patients to have the same power as an individually ran-
domized trial, that is, 24 patients per cluster assuming
that all 12 FPTUs (clusters) will participate. In order to
compensate for loss due to follow up and missing data
( a so b s e r v e di no u rp i l o tR C T ) ,w ew i l lr e c r u i t3 5 0
patients at each data collection period, 175 patients per
group per period.
We will perform descriptive statistical analysis of
socio-demographic characteristics in order to assure the
comparability of both groups (intervention and control).
Potentially confounding variables will be introduced as
covariates in statistical modelling analyses. Multilevel
modelling will be used in order to take the hierarchical
structure of the data into account by specifying random
effects at each of the three levels: FTPU, FP and patient.
For each outcome analysed, according to the type of
variables (continuous or categorical), the goodness of fit
and the assumptions of each model will be assessed. Sta-
tistical analysis will be performed using the SAS statisti-
cal package (SAS Institute Inc. 2005. SAS OnlineDoc
®
9.1.3. Cary, NC: SAS Institute Inc.) and the MLM soft-
ware MLwiN 2.10 Beta.
Discussion
This RCT will be the first study with enough statistical
power to assess the impact of DECISION+2 on reporting
a decision for the immediate use of antibiotics for ARIs in
the context of FPTUs. We expect DECISION+2 to foster
SDM in consultations between FPs and their patients. The
innovative approach proposed in this trial recognizes that
translating and exchanging knowledge and implementing
evidence in clinical practice result from a complex inter-
play of interpersonal elements that influence the clinical
encounter. By revealing as yet unknown mechanisms that
underlie knowledge transfer in the clinical context, DECI-
SION+2 has the potential to foster new knowledge trans-
fer strategies that optimize drug prescriptions.
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